« Return to News | R&D Trends | CROs/Service Providers

Russia approves 95 new clinical trials in first quarter

Monday, June 6, 2011 03:02 PM

The Ministry of Health and Social Development of the Russian Federation (MoH) approved 95 new clinical trials of all types including local studies during the first quarter of 2011, 29% less than the year-ago quarter, according to a quarterly analytical report produced by Moscow-based CRO Synergy Research Group (SynRG).

The quarterly report on Russia’s clinical trial market is another step in improving the research attractiveness of Russia for foreign sponsors, one of SynRG’s goals.

Of the 95 new studies approved, 74 were multi-national, multi-center clinical trials, that number also down 11% from the first quarter of 2010. The number of local clinical trials conducted in Russia by domestic and foreign sponsors is also down from 36 to 18.

Clinical trials in Russia in the first quarter were sponsored by companies from 15 countries. The maximum number of trials—22—was initiated by U.S. sponsors; Russian sponsors had 19 studies; Swiss sponsors had 15 and U.K. companies had 10.

The number of subjects planned for enrollment in phase II-IV trials launched in the first quarter was 11,123 subjects, 15% less than a year ago.

GlaxoSmithKline is sponsoring eight new studies, while Novartis has six new trials, AstraZeneca and Roche each has five, and Sanofi has four.

Of the new studies, 74% were in five leading therapeutic areas: the maximum number of trials—29—was initiated in Oncology; 12 in Respiratory diseases; 11 in Endocrinology; seven in Cardiovascular diseases, and six in Musculoskeletal diseases.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.